DK1208100T3 - Selektive antagonister af A2B adenosinreceptorer - Google Patents

Selektive antagonister af A2B adenosinreceptorer

Info

Publication number
DK1208100T3
DK1208100T3 DK00971055T DK00971055T DK1208100T3 DK 1208100 T3 DK1208100 T3 DK 1208100T3 DK 00971055 T DK00971055 T DK 00971055T DK 00971055 T DK00971055 T DK 00971055T DK 1208100 T3 DK1208100 T3 DK 1208100T3
Authority
DK
Denmark
Prior art keywords
adenosine receptors
selective antagonists
antagonists
selective
adenosine
Prior art date
Application number
DK00971055T
Other languages
Danish (da)
English (en)
Inventor
Italo O Biaggioni
Igor A Feoktistov
Jack N Wells
Original Assignee
Univ Vanderbilt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Vanderbilt filed Critical Univ Vanderbilt
Application granted granted Critical
Publication of DK1208100T3 publication Critical patent/DK1208100T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • AIDS & HIV (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
DK00971055T 1999-08-31 2000-08-28 Selektive antagonister af A2B adenosinreceptorer DK1208100T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15164999P 1999-08-31 1999-08-31
PCT/US2000/040751 WO2001016134A1 (en) 1999-08-31 2000-08-28 Selective antagonists of a2b adenosine receptors

Publications (1)

Publication Number Publication Date
DK1208100T3 true DK1208100T3 (da) 2003-06-30

Family

ID=22539669

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00971055T DK1208100T3 (da) 1999-08-31 2000-08-28 Selektive antagonister af A2B adenosinreceptorer

Country Status (22)

Country Link
EP (1) EP1208100B1 (de)
JP (1) JP3914434B2 (de)
KR (1) KR100502757B1 (de)
CN (1) CN1178940C (de)
AR (1) AR029178A1 (de)
AT (1) ATE236160T1 (de)
AU (1) AU760071B2 (de)
BR (1) BR0013673A (de)
CA (1) CA2383351C (de)
DE (1) DE60001969T2 (de)
DK (1) DK1208100T3 (de)
ES (1) ES2190422T3 (de)
HK (1) HK1049835B (de)
IL (2) IL148366A0 (de)
MX (1) MXPA02002262A (de)
NO (1) NO328489B1 (de)
NZ (1) NZ517546A (de)
PT (1) PT1208100E (de)
TR (1) TR200201132T2 (de)
TW (1) TWI262921B (de)
WO (1) WO2001016134A1 (de)
ZA (1) ZA200201650B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
US6403567B1 (en) 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
CA2671940A1 (en) 2000-02-23 2001-08-30 Cv Therapeutics, Inc. Identification of partial agonists of the a2a adenosine receptor
CA2451244C (en) * 2001-06-29 2012-01-17 Cv Therapeutics, Inc. Purine derivatives as a2b adenosine receptor antagonists
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
WO2005009445A1 (en) * 2003-07-22 2005-02-03 Cv Therapeutics, Inc. A1 adenosine receptor antagonists
JPWO2005053695A1 (ja) * 2003-12-04 2007-12-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 多発性硬化症予防剤または治療剤
BRPI0507604A (pt) * 2004-02-14 2007-07-03 Smithkline Beecham Corp medicamentos com atividade de receptor hm74a
NZ589657A (en) * 2004-10-15 2012-06-29 Gilead Palo Alto Inc Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists
AU2005295437B2 (en) 2004-10-20 2011-05-19 Gilead Palo Alto, Inc. Use of A2A adenosine receptor agonists
ES2270715B1 (es) 2005-07-29 2008-04-01 Laboratorios Almirall S.A. Nuevos derivados de pirazina.
ES2274712B1 (es) 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
WO2007092372A1 (en) 2006-02-03 2007-08-16 Cv Therapeutics, Inc. Process for preparing an a2a-adenosine receptor agonist and its polymorphs
US7795427B2 (en) * 2006-02-14 2010-09-14 New York University Methods for inhibiting osteoclast differentiation, formation, or function and for increasing bone mass
DE102011005232A1 (de) 2011-03-08 2012-09-13 AristoCon GmbH & Co. KG Adenosin und seine Derivate zur Verwendung in der Schmerztherapie
US11370792B2 (en) 2015-12-14 2022-06-28 Raze Therapeutics, Inc. Caffeine inhibitors of MTHFD2 and uses thereof
JOP20210164A1 (ar) 2019-01-11 2023-01-30 Omeros Corp طرق وتركيبات علاج السرطان

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7810946L (sv) * 1978-10-20 1980-04-21 Draco Ab Metod att behandla kronisk obstruktiv luftvegssjukdom
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
KR930703319A (ko) * 1990-12-21 1993-11-29 데이빗 로버츠 키산틴 유도체
GB9210839D0 (en) * 1992-05-21 1992-07-08 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
TWI262921B (en) 2006-10-01
AR029178A1 (es) 2003-06-18
BR0013673A (pt) 2002-05-28
PT1208100E (pt) 2003-07-31
MXPA02002262A (es) 2002-09-30
DE60001969T2 (de) 2004-02-05
ATE236160T1 (de) 2003-04-15
CN1377352A (zh) 2002-10-30
DE60001969D1 (de) 2003-05-08
AU760071B2 (en) 2003-05-08
CN1178940C (zh) 2004-12-08
NO328489B1 (no) 2010-03-01
CA2383351A1 (en) 2001-03-08
KR100502757B1 (ko) 2005-07-22
IL148366A0 (en) 2002-09-12
EP1208100A1 (de) 2002-05-29
HK1049835B (zh) 2005-04-08
IL148366A (en) 2006-12-10
TR200201132T2 (tr) 2002-08-21
NO20020979L (no) 2002-04-26
NZ517546A (en) 2003-10-31
JP2003508398A (ja) 2003-03-04
WO2001016134A1 (en) 2001-03-08
JP3914434B2 (ja) 2007-05-16
EP1208100B1 (de) 2003-04-02
NO20020979D0 (no) 2002-02-27
CA2383351C (en) 2005-11-01
HK1049835A1 (en) 2003-05-30
AU8034800A (en) 2001-03-26
KR20020041419A (ko) 2002-06-01
ZA200201650B (en) 2003-05-28
ES2190422T3 (es) 2003-08-01

Similar Documents

Publication Publication Date Title
DK1208100T3 (da) Selektive antagonister af A2B adenosinreceptorer
DE60110219D1 (de) Adenosin a2a rezeptor antagonisten
IS5706A (is) Adenosín A3 viðtakastillar
DE60026169D1 (de) Selektive neurokinin-antagonisten
ATE317844T1 (de) Adenosine a2a receptor antagonisten
PT1309559E (pt) Derivados de 4-fenil-piridina como antagonistas do receptor de neuroquinina-1
PT1192169E (pt) C-pirazoles agonistas do receptor a2a
HUP0401925A3 (en) A2b adenosine receptor antagonists
DE60234951D1 (de) Adenosin a2a rezeptor antagonisten
ATE368659T1 (de) Thrombinrezeptorantagonisten
PT1131291E (pt) Antagonistas iii do receptor 4-aroil-piperidin-ccr-3
DK1221952T3 (da) Anvendelse af en antagonist til centrale cannaboidreceptorer med henblik på fremstilling af lægemidler
IS2456B (is) Ímídasókínólínafleiður sem adenósín A3 viðtakabindlar
EE200300260A (et) Kondenseeritud puriinderivaadid kui A1 adenosiiniretseptori antagonistid
NO20004503L (no) Vitronectin-reseptor-antagonister
DE69920518D1 (de) Vitronectin rezeptor antagonist
NO20015662L (no) Oralt aktive A1-adenosinreseptorantagonister
NO20010620D0 (no) Vitronektinreseptor-antagonister
EE200100214A (et) Ureidopiperidiini derivaadid kui inimese NK3 retseptorite selektiivsed antagonistid
ATE320254T1 (de) Crf receptor antagonisten
SE0003996D0 (sv) Receptorantagonister
SI1444233T1 (sl) Antagonisti adenozinskega receptorja A2B
TH109999B (th) นิวคลีโอไซด์